birch bark

Last updated on: 15.12.2023

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

s.a. betulin. Initially processed only in care preparations. Since 2016, a gel with birch bark dry extract (72-88 mg betulin per g gel) has been granted approval with the indication "Treatment of superficial skin wounds (epidermis and upper dermis) and grade IIa burn wounds of the skin in adults":

Dry extract (DEV 5-10:1; extraction agent heptane; equivalent to 72-88 mg betulin/g gel) in gel.

Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP): For superficial wounds under the name Episalvan Gel, withdrawn from the market in the meantime.

On 06/24/2022, the EMA Committee for Medicinal Products for Human Use (CHMP) granted marketing authorization to Filsuvez birch bark extract for the treatment of superficial wounds associated with dystrophic and junctional epidermolysis bullosa. The gel is applied locally to the affected skin areas.

Field of application/useThis section has been translated automatically.

Episalvan: as a gel on the skin wound

EMA marketing authorisation recommendation for superficial wounds

EU approval for the treatment of superficial wounds in adults

Undesirable effectsThis section has been translated automatically.

Local itching and pain

PreparationsThis section has been translated automatically.

Episalvan® , but has since been withdrawn from the market, Filsuvez® approved for dystrophic and junctional epidermolysis bullosa, see also Betulin - Imlan Pur® and Implan Plus®

LiteratureThis section has been translated automatically.

  1. https://arzneipflanzenlexikon.info/birch.php
  2. https://arznei-news.de/birch-bark-extract/
  3. https://www.deutsche-apotheker-zeitung.de/news/artikel/2022/04/27/ein-birkenextrakt-gegen-epidermolysis-bullosa
  4. https://arznei-news.de/epidermolysis-bullosa-filsuvez-birch-bark-extract-eu-approval-recommendation/#a2

Last updated on: 15.12.2023